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ARTICLE
The neutrophil antimicrobial peptide cathelicidin
promotes Th17 differentiation
Danielle Minns1, Katie J. Smith1, Virginia Alessandrini1, Gareth Hardisty1, Lauren Melrose1, Lucy Jackson-Jones2,
Andrew S. MacDonald 3, Donald J. Davidson 1 & Emily Gwyer Findlay 1✉
The host defence peptide cathelicidin (LL-37 in humans, mCRAMP in mice) is released from
neutrophils by de-granulation, NETosis and necrotic death; it has potent anti-pathogen
activity as well as being a broad immunomodulator. Here we report that cathelicidin is a
powerful Th17 potentiator which enhances aryl hydrocarbon receptor (AHR) and RORγt
expression, in a TGF-β1-dependent manner. In the presence of TGF-β1, cathelicidin enhanced
SMAD2/3 and STAT3 phosphorylation, and profoundly suppressed IL-2 and T-bet, directing
T cells away from Th1 and into a Th17 phenotype. Strikingly, Th17, but not Th1, cells were
protected from apoptosis by cathelicidin. We show that cathelicidin is released by neutrophils
in mouse lymph nodes and that cathelicidin-deficient mice display suppressed Th17
responses during inflammation, but not at steady state. We propose that the neutrophil
cathelicidin is required for maximal Th17 differentiation, and that this is one method by which
early neutrophilia directs subsequent adaptive immune responses.
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The last 20 years have seen a fundamental shift in ourunderstanding of the roles and capabilities of neutrophils.We are now aware that they can live for much longer than
previously thought (up to 5 or 6 days in vivo1); that they move
into lymphatics, both during inflammation and as part of regular
homoeostatic control2–8; that they can have reparative as well as
pro-inflammatory roles9–14; and that they influence outcomes in
chronic inflammatory and autoimmune diseases, as well as in
infections15–17. As a result, we now recognise neutrophils as able
to influence and shape adaptive immunity in tissues and in
lymph nodes, in both suppressive and activatory manners
(reviewed in18,19). For example, neutrophils restrain Th2
inflammation during asthma20, suppress dendritic cell (DC)
migration to lymph nodes21, suppress T cell proliferation in
sepsis via Mac-122, and limit humoral responses in lymph
nodes23. In contrast, they can also directly present antigen to
T cells via MHC class II24, cross-present to CD8+ T cells25,
directly stimulate T cell proliferation in response to super-
antigen26, promote type 2 responses in the lung27, increase DC
maturation and co-stimulatory molecule expression16,28–30 and
promote T cell function during influenza infection31,32.
A particular relationship between neutrophils and the IL-17-
producing Th17 subset of CD4+ T cells is now evident. The two
cells chemoattract each other to the site of inflammation through
production of CCL20/22, IL-17 and IL-833, and the production of
IL-17A and IL-17F by Th17 cells increases epithelial cell release of
G-CSF and CXCL8, increasing neutrophil migration and activa-
tion34. Following release of extracellular traps, the surviving
neutrophil cytoplast structures can indirectly induce Th17 dif-
ferentiation in the lung during severe asthma35. Neutrophils also
produce the Th17 differentiation cytokine IL-2336, their elastase
release processes DC-derived CXCL8 into a Th17-promoting
form37, and in vitro they can induce Th17 differentiation
directly38. However, the mechanisms through which this occurs
largely remain unknown.
A major component of neutrophil secondary granules39,40 and
extracellular traps41 is the short helical antimicrobial host defence
peptide (HDP) cathelicidin (human hCAP-18/LL-37, mouse
mCRAMP). It can also be produced to a lesser extent by mac-
rophages, mucosal epithelium, eosinophils, adipocytes42 and mast
cells. Release of HDP, such as cathelicidin, is a critical part of the
first line innate immune response to infection43,44 and it is
antibacterial, antiviral, antifungal and immunomodulatory45–47,
with potent ability to modulate the local innate and adaptive
immune response. Amongst other effects, it can act as a che-
moattractant for immune cells48,49, promote protective inflam-
matory responses and modulate cell death50,51, induce wound
healing, re-epithelialization and re-endothelialization52,53, allow
the take-up of self-RNA and production of type one interferons
by plasmacytoid DC54,55 and inhibit class switching in B cells56.
We and others have previously shown cathelicidin to directly
and indirectly affect T cell function; it induces DC to prime
increased proliferation and pro-inflammatory cytokine produc-
tion by CD8+ T cells57, is a chemoattractant for T cells48, and, in
psoriasis, it is recognised directly as an autoantigen by CD4+
T cells58.
The outcome of neutrophil cathelicidin-CD4+ T cell interac-
tion is largely uncharacterised. In this project we set out to
investigate how cathelicidin affected T cell differentiation. We
report that cathelicidin is a potent T cell differentiation factor,
which induces Th17 and suppresses Th1 differentiation during
inflammation, as well as selectively suppressing death of IL-17
producing cells. We show that this is partially dependent on both
the aryl hydrocarbon receptor and the presence of TGF-β1 and
propose this as a major mechanism by which neutrophils can
direct T cell behaviour during inflammatory disease.
Results
The host defence peptide cathelicidin induces IL-17A produc-
tion by CD4+ T cells. Following on from reports that neutrophils
can induce IL-17A production, we hypothesised that cathelicidin
specifically affects differentiation of Th17 cells. To examine this
we exposed splenic single-cell suspensions from C57BL/6 J mice
to Th17-driving conditions. Some wells were exposed to the
murine cathelicidin mCRAMP at 2.5 µM, which is a physiologi-
cally relevant concentration (with cathelicidin in airway secre-
tions from healthy newborns averaging 2 µM and from those with
pulmonary infections up to 6.5 µM59). Analysis was performed
using the flow cytometry gating strategy in Supplementary Fig. 1.
We noted a consistent increase in the frequency of IL-17A
producing CD4+ T cells in culture following cathelicidin
exposure under Th17-driving conditions (Fig. 1A, B). The total
count of CD4+ cells in culture did not change significantly, from
a mean of 33.5 ± 4.8 × 103 CD4+ T cells in control samples to
38.1 ± 5.9 × 103 cells in cathelicidin-exposed samples. Further, we
noted that under non-polarising T cell activation conditions
(αCD3/αCD28 stimulation), cathelicidin induced no increase in
IL-17A production (Fig. 1C), indicating this peptide is unable to
act alone, instead boosting pathways which have already been
triggered.
Further investigation with whole splenic cultures revealed
that this increase was dependent on both the concentration of
cathelicidin present (Fig. 1D) and the time in culture (Fig. 1E);
cathelicidin exposure led to a 2.5-fold increase in IL-17A
production by day 2 of culture, with further increases seen
on day 3. Not only the frequency of IL-17A+ cells but also
the intensity of IL-17A expression (Fig. 1F) was increased
following cathelicidin exposure, with consequent increased
detection of IL-17A by ELISA in cell culture supernatant on
day 2 (Fig. 1G).
Th17 cells are characterised by expression of the transcription
factor RORγt60,61. In keeping with this, cathelicidin also induced
strong expression of RORγt in CD4+ T cells following 24 h in
culture (Fig. 1H, I). To confirm that our cathelicidin-induced cells
are indeed Th17 cells, we co-stained for RORγt and IL-17 and
demonstrated that all the IL-17-producing cells induced by
cathelicidin were RORγt+ (Fig. 1J).
We confirmed that cathelicidin was enhancing differentiation
of these cells directly by isolating splenic CD4+ T cells and
exposing them to cathelicidin under Th17-driving conditions
(Fig. 1K). IL-17A production by these sorted cells was
significantly increased by cathelicidin, with an average 6.2-fold
increase in frequency of RORγt+ IL-17A+ cells after 48 h culture
and 4-fold increase after 72 h culture (Fig. 1K).
In addition, we assessed phosphorylation of STAT3.
STAT3 signalling is required for Th17 but not Th1 differentia-
tion62. In isolated CD4+ T cells exposed to cathelicidin for 24 h
under Th17-driving conditions, STAT3 phosphorylation was
significantly enhanced (Fig. 1L–N).
Cathelicidin’s induction of IL-17 is dependent on TGF-β1
signalling. Our Th17-driving conditions include αCD3 and
αCD28 antibodies, and recombinant IL-6, TGF-β1 and IL-23. To
examine whether cathelicidin enhances the signalling of any of
these mediators specifically, we assessed its impact on RORγt
expression in the presence of each mediator individually.
Cathelicidin induced increases in RORγt expression only in the
presence of TGF-β1 (Fig. 2A), with no increases seen in cells
treated with IL-6 alone, IL-23 alone or IL-6 and IL-23 in com-
bination. Cathelicidin enhanced RORγt in the presence of TGF-
β1 alone, but peak expression following cathelicidin exposure
occurred in the presence of IL-6 as well as TGF-β1.
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We therefore hypothesised that cathelicidin was enhancing
TGF-β1 signalling. It was also possible that the peptide enhanced
expression of the TGF-β receptor. Analysis of CD4+ T cells
exposed to cathelicidin in Th17-driving conditions revealed that
this receptor—and IL-6R and IL-23R—were unaltered (Fig. 2B,
C). However, phosphorylation of the Smad2/3 signalling proteins
was significantly increased by cathelicidin exposure (Fig. 2D, E).
Smad2 and 3 are phosphorylated following TGF-β1 signalling63
and so this indicated that cathelicidin was indeed enhancing this
process.
IL-1β has also been shown to induce Th17 differentiation64,65.
Cathelicidin induced Th17 differentiation when IL-1β was
included in our cultures, but only when TGF-β1 was present,
and this was not enhanced over our normal culture conditions of
IL-23, IL-6 and TGF-β1 (Fig. 2F).
Cathelicidin has been shown to use multiple receptors,
including P2X7R, CXCR2, GAPDH and FPR248,66–70. It can also
enter cells—including plasmacytoid DC, fibroblasts, CHO
epithelial cells and bladder carcinoma cells—without a receptor,
via lipid-raft dependent endocytosis55,71. To determine whether
cathelicidin’s increase in IL-17A was dependent on a specific
receptor, we also used the human cathelicidin LL-37 and the
matched D-enantiomer D-LL-37. LL-37 induced the same increase
in IL-17A in mouse cells as the murine cathelicidin mCRAMP did;
in addition, the D-form peptide D-LL-37 induced a strong increase
in IL-17 (UT cells 9.45 ± 0.47%, D-LL-37 16.2 ± 1.01%) (Fig. 2G).
Fig. 1 The antimicrobial peptide cathelicidin induces IL-17A production by CD4+ T cells. Splenocytes isolated from C57BL/6 J mice were cultured in
Th17-driving conditions for 48 h in the presence or absence of 2.5 μM murine cathelicidin. A, B Expression of cytokines was determined by intracellular
flow cytometry. C Splenocytes were cultured with αCD3αCD28 stimulation alone with cathelicidin. D Production of IL-17A following increasing doses of
cathelicidin (for 48 h) and E prodution over increasing days in culture was assessed. F Geometric mean of IL-17A expression was also assessed at 48 h.
G After 72 h of culture supernatant was collected and IL-17A protein quanitified by ELISA. H Representative flow cytometry plots showing RORγt
expression; I RORγt expression was quantified over time in culture. J At 48 h in culture all IL-17+ cells were RORγt+. K Sorted CD4+ T cells were cultured
alone in Th17-driving confitions for 48 or 72 h. L–N Following 24 h culture of sorted CD4+ T cells STAT3 phosphorylation was assessed by flow cytometry.
Data shown are individual mice used in separate experiments with line at median. Statistical signficance was determined using a one-way ANOVA with
Sidak’s post-test (E, I), a two-tailed paired t-test with no corrections (B, G, F, G, K,M, N) or a one-way ANOVA with a Dunnett’s multiple comparison post-
test (D). N values: B - 17, C - 6, D - 3, E - 6, F - 24, G - 7, I - 6, K - 4, M - 3, N - 3. Black symbols represent untreated samples and open symbols represent
samples exposed to cathelicidin.
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These results suggest that cathelicidin is functioning to modify
CD4+ T cell phenotype in a manner independent of the peptide
binding to a receptor directly.
To examine this further, we performed our Th17 generation
assay in the presence of WRW4, an inhibitor of FPR2, and
oxidised ATP (oATP), an inhibitor of P2X7 signalling. Including
WRW4 in our cultures had no impact on total IL-17 production
(Fig. 2H). However, we noted a concentration-dependent
suppression of cathelicidin’s potentiation of Th17 in the presence
of oATP, with 50 nM preventing cathelicidin from enhancing IL-
17 production (Fig. 2I). This was not statistically significant
owing to an increase in baseline IL-17A production in cells
exposed to oATP.
Together, these results reveal that the antimicrobial peptide
cathelicidin significantly promotes Th17 differentiation and IL-
17A production in a TGF- β1 dependent fashion.
Fig. 2 Cathelidin-mediated induction of IL-17A is dependent on TGF-β signalling. Splenocytes isolated from C57BL/6 J mice were cultured in Th17-
driving conditions for 48 h in the presence or absence of 2.5 μM cathelicidin. A Expression of RORγt following incubation with each component of the Th17
medium was assessed. B, C Expression of cell surface cytokine receptors was quantified by flow cytometry. D, E Following 24 h in culture of isolated
CD4+ T cells, phosphorylation of SMAD2/3 was determined. F IL-1β was included in cell cultures and IL-17A production assessed. G Different cathelicidin
peptides were included in the cultures and H, I inhibitors of cell surface receptors for cathelicidin. Data shown are individual mice treated separately with
line at median. Statistical significance was deetermined using a two-way ANOVA with Sidak’s post-test (A, I), a paired two-tailed t-test with no corrections
(E, H, F), or a one-way ANOVA with a Tukey’s multiple comparison post-test (G). N values: A - 4, C - 3 for IL-23R and IL-6r, 4 for TGF-bR, E - 3, F - 3, G - 8
for UT and CRAMP, 3 for LL-37 and D-LL-37,.H - 3, I - 6 for 0 nM, 3 for 10 and 50 nM. Black symbols rrepesent untreated samples and open symbols
represent samples treated with cathelicidin.
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Cathelicidin induces IL-17F-producing but not IL-22-producing
cells. Th17 cells produce a number of pro-inflammatory cytokines
including IL-17A, IL-17F and IL-2272–74. We wondered whether
cathelicidin would increase expression of these other cytokines in
addition to IL-17A. Analysis of cathelicidin-exposed CD4+ T cells
showed, surprisingly, that cathelicidin did not boost IL-17A single
positive (SP) cells (Fig. 3A, B). Instead, IL-17F single positive and
A+ F+ double positive cells were significantly increased by treat-
ment (Fig. 3C, D). Consequently production of IL-17F in the
supernatant, as measured by ELISA, was also increased con-
sistently in every sample, although variability between samples
meant this was not statistically significant (Fig. 3E). Interestingly,
production of IL-22 was not altered by cathelicidin (Fig. 3F).
Cathelicidin-mediated enhancement of IL-17A production, but
not IL-17F, occurs via the aryl hydrocarbon receptor. Next, to
understand more about the induction of Th17 cells by cathe-
licidin, we performed gene expression analysis on sorted CD4+
T cells exposed to Th17-driving conditions in the presence or
absence of 2.5 µM cathelicidin for 24 hours, using a Nanostring
mouse immunology chip. Following cathelicidin exposure, we
noted a consistent, significant decrease in the expression of a
number of genes which suppress the induction or conversion of
cells into the Th17 subset75–78 including Socs3, Stat1, Irf8, Bcl3
and Ikzf4 (Fig. 4A, B).
In keeping with our initial observations, cathelicidin exposure
increased expression of the genes coding for IL-17A and the Th17
cytokine IL-21 (Fig. 3A, C). Intriguingly, cathelicidin also led to a
large increase in expression of the aryl hydrocarbon receptor
(AHR) gene Ahr (Fig. 4A, C). Flow cytometric analyses
subsequently confirmed an increase in AHR protein following
cathelicidin exposure under Th17-driving conditions (Fig. 4D, E),
which occurred with increasing time of exposure to cathelicidin
and increasing concentration of the peptide present (Fig. 4E, F).
The increase in AHR expression by cathelicidin was significant
after one day in culture (Fig. 4E), which is earlier than the IL-17
increase was noted.
AHR is a known Th17 differentiation factor73,75,79 and so we
hypothesised that the cathelicidin-mediated increase in IL-17 was
a result of its enhanced expression. To test this, we used the
specific AHR antagonist CH22319180. Use of CH223191
abolished the increase in IL-17A+F+ double-producing cells
induced by cathelicidin, indicating that cathelicidin’s induction of
these Th17 cells is dependent on AHR (Fig. 4G). Interestingly,
single IL-17F-producing cells were increased by cathelicidin, as
previously shown (Fig. 3C), but this increase was not significantly
altered by AHR antagonism (Fig. 4H). These results indicate
that there are both AHR-dependent and—independent mechan-
isms through which cathelicidin promotes Th17 differentiation,
with AHR being critical for the enhanced generation of IL-
17A producing cells, but not the increase in cells producing only
IL-17F.
Finally, we questioned whether cathelicidin-mediated enhance-
ment of AHR was the key factor in Th17 potentiation or whether it
Fig. 3 Cathelicidin induces IL-17F-producing but not IL-22-producing T cells. Splenocytes isolated from C57BL/6 J mice were cultured in Th17 conditions
for 48 h in the presence or absence of 2.5 μM cathelicidin. A–D Expression of IL-17A and F was determined by intracellular flow cytometry. E IL-17F
and F IL-22 production was quantified by ELISA of cell culture supernatant after 48 h in culture. Data shown are individual mice in separate experiments.
B–F are analysed by paired two-tailed t-tests. SP= single positive. N values: B - 9, C - 9, D - 9, E - 5, F - 4. Black symbols represent untreated samples and
open symbols are samples treated with cathelicidin.
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also increased the production of AHR ligands. To answer this, we
repeated our Th17 differentiation cultures in IMDM as well as in
RPMI. It is known that IMDM contains more natural AHR ligands
which induce Th17 differentiation81. Cathelicidin enhanced Th17
differentiation equally in RPMI and IMDM (Fig. 4I), indicating that
this potentiation occurs even when AHR ligands are in excess. This
lends support to our hypothesis that the expression of AHR itself is
the key factor in cathelicidin’s enhancement of Th17, meaning that
cathelicidin can potentiate AHR signalling and Th17 differentiation
at both high and lower ligand levels.
Cathelicidin suppresses Th1 differentiation in the presence of
TGF-β1. Gene expression analysis also revealed a consistent
decrease in Th1-associated genes, including Il2, Irf8, Stat1, and
Fig. 4 Cathelicidin induces Th17 cells via AHR up-regulation. CD4+ T cells isolated from C57BL/6 J mice were cultured in Th17-driving conditions
for 24 h in the presence or absence of 2.5 μM cathelicidin. A–C gene expression differences were assessed by a Nanostring mouse immunology chip.
D Representative flow cytometry plots showing aryl hydrocarbon receptor staining which was assessed over time in culture (E) and over increasing
concentrations of cathelicidin (F). G, H IL-17A and F production was assessed by flow cytometry following blockade of AHR with the antagonist CH223191
(ant.). I Th17 cultures were repeated using IMDM as well as RPMI medium. Data shown are individual mice with line at medium. Statistical significance
was assessed using (B, C) a paired two-tailed t-test with Bonferroni post-test, E repeated measures ANOVA with Sidak’s post-test, F Kruskal–Wallis test,
G, H two-way ANOVA with Tukey’s post-test and I two-tailed t-test with no correction. N values: B- 3, C - 3, E - 3, F - 3, G - 5, H - 5, I - 3. The error bars in
I show standard error of the mean. Black symbols represent untreated samples and open symbols are samples treated with cathelicidin. Red symbols show
samples treated with AHR antagonist.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21533-5
6 NATURE COMMUNICATIONS |         (2021) 12:1285 | https://doi.org/10.1038/s41467-021-21533-5 | www.nature.com/naturecommunications
Xcl1 (Fig. 4A) following 24 hours of cathelicidin exposure in cells
differentiating under Th-17 driving conditions. Expression of IL-
2 protein was confirmed to be reduced following cathelicidin
exposure on day 2 of culture (Fig. 5A), with a striking suppression
of IL-2 production by CD4+ T cells, as measured by ELISA.
Expression of the Th1-associated transcription factor Tbet (Fig.
5B) and production of the key Th1 cytokine IFN-γ (Fig. 5C, D)
were also both strongly suppressed by cathelicidin.
It was very interesting that Tbet was suppressed when RORγt
was up-regulated, and we wondered if any double positive
(RORγt+ Tbet+ cells) were present in our culture, and whether
they expressed IL-17. We found that under Th17-driving
conditions almost all the Tbet+ cells also expressed RORγt
(Fig. 5E). Tbet single-positive cells were almost abolished in
cathelicidin-exposed cultures, and the Tbet+ RORγt+ double
positive population was also significantly suppressed. Instead,
cathelicidin polarised the cells to RORγt single expressors
(Fig. 5E).
Next, we examined the cytokine production by each of these
populations, gating on transcription factor expression. We noted
that cathelicidin strongly suppressed the tiny populations of
Th1 cells (RoRγt- Tbet+ IFNγ+ ), to confirm our previous findings
that cathelicidin suppresses Th1 cell differentiation (Fig. 5F). We
also found that cathelicidin enhanced IL-17 production (total IL-
17A+ and IL-17F+ ) by both single expressing RORγt+ and double
expressing Tbet+ RORγt+ cells, although the increase in the latter
population was much lower (Fig. 5G, H).
It is well known that Th17-driving conditions do suppress IL-2
production and Th1 commitment82,83 and we proposed that
cathelicidin boosts this suppression further through enhancing
TGF-β1 signalling. In keeping with this, we determined that
cathelicidin had no impact on Tbet expression in activating non-
lineage driving conditions (αCD3, αCD28) but only when TGF-
β1 was present (Fig. 5I)—and the presence of TGF-β1 alone was
sufficient for cathelicidin to induce this suppression. To confirm
this, we analysed production of IFN-γ under Th1-driving and
Th2-driving conditions, neither of which include TGF-β1.
Cathelicidin did not suppress IFN-γ in these conditions (Fig.
5J). This demonstrates a further enhancement of TGF- β1’s action
by cathelicidin.
Cathelicidin promotes survival of Th17 cells but not Th1 cells.
We have shown that cathelicidin promotes increased differ-
entiation of Th17 cells with suppression of Th1 cells in the pre-
sence of TGF- β1. We next investigated whether, in addition to
modulated differentiation of CD4+ T cells, cathelicidin also led to
differential survival or proliferation of particular cell subsets.
Cathelicidin has been previously shown to induce death of certain
T cell subsets, including T regulatory cells and CD8+ T cells,
although CD4+ T effector cells were not affected84,85. Our
Nanostring gene expression analysis revealed a significant down-
regulation of Fasl and consistent but not significant down-
regulation of Fas in sorted CD4+ T cells 24 hours following
cathelicidin exposure (Fig. 6A). Subsequently, to determine
whether this led to altered rates of death of CD4+ T cells, we
measured annexin V staining and uptake of propidium iodide,
which together distinguish between live, apoptotic and necrotic
cells. Using this method, we noted that cathelicidin significantly
suppressed death of CD4+ T cells, with effects seen by the first
day of culture (Fig. 6B,C).
To investigate suppression of death by cytokine producing cells
in particular, uptake of fixable live dead dyes was assessed
(Fig. 6D). Interestingly, cathelicidin exposure suppressed death of
IL-17A-producing CD4+ T cells (Fig. 6D, E) but not IFN-γ-
producing cells (Fig. 6F), in the same samples, under Th17-
driving conditions. To our knowledge, this is the first demonstra-
tion of a neutrophil-released peptide, or of any antimicrobial
peptide, increasing survival of T cells. These data raise the
possibility that neutrophils may have sophisticated impacts on
developing and skewing T cell immunity during inflammatory
disease. It was possible that the increased survival of T cells
exposed to cathelicidin was related to the altered IL-2 concentra-
tions noted earlier. To test this, we spiked our Th17 cultures with
increasing concentrations of recombinant IL-2 and found no
alteration in cathelicidin’s enhancement of survival (Fig. 6G).
Another possibility was that cathelicidin induces increased
proliferation of Th17 cells but not Th1 cells, and that this
contributes to their increased frequency in culture. CD4+ T cells
labelled with CFSE were observed following exposure to
cathelicidin. We noted that there was no difference in the
proliferation of RORγt+ Th17 cells at 24 or 48 hours in culture,
but at 72 hours differences were noted (Fig. 6H). Surprisingly,
cathelicidin induced a suppression in proliferation of RORγt+
cells at this time point, and this was not rescued by addition of
recombinant IL-2. The proliferation of Tbet+ cells, interestingly,
was not significantly suppressed by cathelicidin (Fig. 6I,J).
Mice lacking cathelicidin cannot increase IL-17 production in
response to inflammation. Next, we questioned whether our
results extended in vivo, and whether T cells differentiate in an
altered manner in cathelicidin knockout (Camptm1Rig, KO) mice.
Firstly we assessed whether KO mice had altered Th17 cell
numbers in the steady state. Analysis of ex vivo T cell cytokine
production in multiple organs revealed no differences between
KO and wild-type C57BL/6JOlaHsd (WT) mice (Fig. 7A,B) –
indicating that cathelicidin is not required for development of
Th17 cells in the steady state.
We hypothesised that while cathelicidin has no impact on T
cell development, it may affect Th17 differentiation during
inflammation, when it is released by neutrophils and other cells.
To investigate the impact of cathelicidin in the context of
inflammation, we used a vaccination model. WT and KO mice
were inoculated with heat-killed Salmonella typhimurium
(HKST) into the top of each hind paw. Seven days later draining
popliteal lymph nodes were removed and IL-17A quantified by
flow cytometry. KO lymph node CD4+ T cells were unable to
produce IL-17A to the same level as WT T cells (Fig. 7C),
confirming that cathelicidin promotes Th17 differentiation
in vivo as well as in vitro.
This experiment did not tell us if the T cells themselves were
inherently different in KO mice or unable to produce IL-17. To
test this, we firstly stimulated KO splenic T cells in vitro. In the
presence of Th17-driving cytokines, CD4+ T cells from KO mice
could produce IL-17 to a level equivalent to wild-type cells (Fig.
7D). Secondly, we performed an adoptive transfer of OT-II CD4+
T cells into WT and KO mice and immunised the mice with
ovalbumin in complete Freund’s adjuvant. Analysis of donor
T cells in draining inguinal lymph nodes and spleens 7 days later
showed significantly lower IL-17A production by donor T cells
introduced into KO mice (Fig. 7E). In addition, the percentage
(Fig. 7F) and number (Fig. 7G) of OT-II cells recovered from
KO mice were significantly lower than in WT mice, supporting
our earlier in vitro findings that cathelicidin enhances survival
of these cells. These two experiments combined led us to conclude
that (a) cathelicidin is not absolutely required for Th17
differentiation or for baseline production of IL-17 but (b)
in the context of inflammation, cathelicidin potentiates Th17
differentiation and IL-17 production. They also demonstrated
that our in vitro observation that cathelicidin is a Th17
differentiation factor was relevant in vivo.
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Fig. 5 Cathelicidin suppresses TH1 differentiation in the presence of TGF-β1. Splenocytes from C57BL/6 J mice were cultured in Th17-driving conditions
for 48 h in the presence or absence of 2.5 μM cathelicidin. A production of IL-2 was quantified by ELISA and B–D expression of Tbet and IFN-γ were
assessed by flow cytometry. E Tbet and RORγt co-expression was quantified by flow cytometry and F–H the cytokine production by each subset assessed.
I Tbet expression was determined following incubation with individual cytokines. J IFN-γ production was quantified by ELISA after 48 h incubation under
Th1-driving or Th2-driving conditions. Data shown are individual mice used in separate experiments. A, B, D, E, F, G, H and I were analysed by paired two-
tailed t-tests with no correction, N values: A - 4, B - 6, D - 12, E - 9, F - 9, G - 9, H - 9, I - 4, J - 3. The error bars in J show standard error of the mean. Black
symbols represent untreated samples and open symbols are samples treated with cathelicidin.
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Fig. 6 Cathelicidin protects Th17 cells but not Th1 cells from death. CD4+ T cells isolated from C57BL/6 J mice were cultured in Th17-driving conditions
for 24 h in the presence or absence of 2.5 μM cathelicidin. A Gene expression differences were assessed by Nanostring mouse immunology chip. Cell death
was assessed in culture by B, C annexin V/propidium iodide staining and D–F binding of a fixable live/dead marker. G Annexin/PI staining was repeated at
48 h of culture following inclusion of IL-2 in culture medium. H–J T cells were labelled with CFSE and proliferation assessed following 24, 48 or 72 h culture
—I and J show 72 h culture analysis. Data shown are individual mice used in separate experiments with line at median. A, E, F and I were analysed with
paired two-tailed t-tests—A and I with Bonferroni post correction, C and G with a two-way ANOVA with Sidak’s post-test. N values: A - 3, C - 6,
E - 20, F - 19, G - 5, I - 3, J - 3. Black symbols represent untreated samples and open symbols are samples treated with cathelicidin.
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Cathelicidin is released in the lymph nodes by neutrophils.
Repeating our in vitro culture experiments with Th17-driving
medium, we found that cathelicidin needed to be present in the
first 24 hours of culture in order to induce Th17 differentiation
(Fig. 8A), with its addition to activated cells leading to no dif-
ferences in IL-17 production. This suggests that, in vivo, it would
only promote Th17 differentiation if present in lymph nodes
during the antigen presentation process, and would not have an
enhancing effect in the tissue if interacting with T cells which are
already activated and differentiated.
We did not know whether or when cathelicidin was produced
in the lymph nodes. To determine this, we examined lymph
nodes over a time course of HKST injection. Cathelicidin was not
present in the steady state lymph node but appeared on day one
following inoculation and was strongly present at day 7 (Fig. 8B).
Interestingly, we noted the presence of extracellular cathelicidin
(arrow heads, Fig. 8B) which had been released from cells.
Co-staining lymph node sections revealed that the vast majority of
cathelicidin-expressing cells were neutrophils, with 85% of cathe-
licidin signal on day 7 being associated with co-staining for the
neutrophil marker Ly6G (total cathelicidin+ cells counted over three
lymph nodes = 366, of which 55 were Ly6G- and 311 Ly6G+ )
(Fig. 8C). We therefore hypothesised that neutrophils were releasing
cathelicidin in the lymph nodes and enhancing Th17 differentiation.
Firstly, we confirmed that KOmice did not have an intrinsic defect
in neutrophil migration. Following HKST inoculation, neutrophil
numbers in the draining lymph node were equivalent between WT
and KO mice (Fig. 8D). Next, we examined IL-1β in this system. We
did not note a significant change in lymph node IL-1β following
HKST inoculation in WT compared to KO mice (Fig. 8E).
We examined whether neutrophil release of cathelicidin could
induce Th17 differentiation in vitro. Neutrophil-induced produc-
tion of IL-17 has previously been demonstrated86. Here, we used
mouse bone marrow-isolated neutrophils from WT or KO mice,
which had been activated by 30 min incubation with fMLF and
cytochalasin B, to induce de-granulation. The neutrophils were
included in culture wells with WT CD4+ T cells, at a 1:1 T cell:
neutrophil ratio and in Th17-driving conditions. WT neutrophils
induced IL-17A production by CD4+ T cells (Fig. 8F) but KO
neutrophils did not, although the positive control cathelicidin
demonstrated that the experiment had worked as normal (Fig.
8G). This data demonstrates that the increase in IL-17A
production induced by de-granulating neutrophils is owing to
their release of cathelicidin. In addition, AhR expression was
significantly lower in T cells co-cultured with KO neutrophils
compared to WT neutrophils (Fig. 8H) and blocking cathelicidin
from WT neutrophils with an antibody suppressed IL-17A
enhancement from sorted CD4+ T cells (Fig. 8I). Finally, we
examined responses to an infection model in addition to
vaccination. As cathelicidin is directly antimicrobial, it is difficult
to decipher its immunomodulatory roles separately to its microbial
killing. However, we have previously demonstrated that cathelicidin
dramatically enhanced survival in a murine influenza virus infection
model, despite only small changes in viral load, suggesting a key
immunomodulatory component to protection87. We therefore
infected WT and cathelicidin KO mice with PR8 influenza and
removed the draining mediastinal lymph nodes on day 3 post
infection. In agreement with the evidence presented in this paper,
IL-17A production in the KOmice was substantially (but not totally)
suppressed, when compared to WT mice (Fig. 8J).
Fig. 7 Mice lacking cathelicidin cannot increase IL-17A production in response to inflammation. Wild-type (WT) C57BL/6 J and fully backcrossed
cathelicidin knockout (Camp−/−, KO) mice were culled and A, B organs removed and IL-17A production assessed ex vivo by flow cytometry. C Mice
were inoculated with 12.5 μg/ml heat-killed Salmonella typhimurium and draining lymph nodes removed seven days later—IL-17A was measured by flow
cytometry. D Splenic T cells from WT or KO mice were stimulated in Th17-driving conditions for 48 h and IL-17A quantified by flow cytometry. E–G WT
and KO mice were injected intravenously with 5 million OT-II T cells and 24 h given ovalbumin in complete Freund’s adjuvant subcutaneously. On day
7 spleens and lymph nodes were removed and donor cell survival and IL-17A production assessed by flow cytometry. Data shown are individual mice with
line at median. C–G were analysed with two-tailed t-tests with no correction. PP—Peyer’s Patches; mLN = mesenteric lymph node. N values: B - 4,
C - 3, D - 4, E - 4, F - 4, G - 4. Black symbols represent wild-type mice and open symbols represent mice lacking cathelicidin.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21533-5
10 NATURE COMMUNICATIONS |         (2021) 12:1285 | https://doi.org/10.1038/s41467-021-21533-5 | www.nature.com/naturecommunications
Cathelicidin induces IL-17A production from human CD4+
T cells. Finally, to assess whether our observations held true for
human cells, we isolated CD4+ T cells from peripheral blood of
healthy human donors and incubated them with 2.5 µM human
cathelicidin (LL-37) under Th17-driving conditions. Production
of IL-17A was greater in cathelicidin-exposed cells than in con-
trols, measured by flow cytometry on day 8 of culture (Fig. 9A,B)
and ELISAs on days 3 and 8 (Fig. 9C). In addition, IL-17F was
Fig. 8 Cathelicidin is released in the lymph node by neutrophils. A IL-17A production was assessed by flow cytometry following cathelicidin being added
to mouse Th17-driving cultures on day 0 or day 1. B, C Wild-type C57BL/6 J mice were inoculated with 12.5 μg heat-killed Salmonella typhimurium (HKST)
and draining lymph nodes removed 7 days later. Lymph nodes on day 0 and 7 were assessed for presence of cathelicidin (B, arrow heads indicate
cathelicidin not associated with cells) and the association of cathelicidin with the neutrophil marker Ly6G (C). D HKST inoculation of WT and cathelicidin
knockout (KO) mice was performed and 24 h later infiltration of neutrophils into the draining popliteal lymph nodes quantified by flow cytometry. E IL-1β
release was also quantified at 24 h post inoculation. Neutrophils were isolated from the bone marrow of FWT and G KO mice, primed, and added to Th17-
driving cultures of splenic T cells for 48 h before IL-17A production was assessed by flow cytometry and H AHR expression was assessed. I primed
neutrophils fromWT mice in the presence or absence of a cathelicidin-blocking antibody were included in Th17 cultures and IL-17A assessed. JWT and KO
mice were infected intra-nasally with 12pfu PR8 influenza and draining mediastinal lymph nodes removed 72 h later. IL-17A production was quantified by
flow cytometry. Data shown are individual mice with line at median, B and C are representative of 3 experiments. Statistical tests used: A, I one-way
ANOVA with Dunnett’s post-test; E, F, G, H and J paired two-tailed t-test with no correction. N values: A - 3, D - 3, E - 3, F - 8, G - 3, H - 5 for cath., 4 for
neutrophils, I - 3, J - 3. The error bars in H show standard error of the mean. Black symbols—untreated samples, open symbols—cathelicidin treated. Red
closed symbols—exposed to wild-type neutrophils, red open symbols—exposed to KO neutrophils. Red triangles—exposed to neutrophils and anti-
cathelicidin.
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also produced at higher levels in response to cathelicidin
(Fig. 9D). Interestingly, in contrast, IL-22 production was lower
after cathelicidin exposure (Fig. 9E).
Discussion
We demonstrate that the mouse and human antimicrobial host
defence peptide cathelicidin (LL-37/ mCRAMP) induces differ-
entiation of Th17 cells in vitro and in vivo. Specifically, CD4+
T cells exposed to cathelicidin (a) up-regulated AHR, RORγt, IL-
17A and IL-17F (b) down-regulated IL-2, IFN-γ and Tbet and (c)
survived in greater numbers than their untreated controls. This
work extends previous studies showing that neutrophils and Th17
cells amplify each others’ responses (reviewed in18), providing an
explanation for how neutrophils specifically promote one subset
of T cells above others.
Cathelicidin exposure led to a 6-fold increase in production of
IL-17A in sorted CD4+ T cells (Fig. 1D), and a 2.5-fold increase
in production by CD4+ T cells in whole splenic cultures (Fig. 1E).
This compares to a 2.5-fold increase in IL-17A production by the
aryl hydrocarbon receptor FICZ75 and a 3-4-fold increase in IL-
17A mRNA by the same reagent73. These results therefore
identify cathelicidin as of equal potency to one of the most
important Th17 inducers known.
We show that cathelicidin specifically increases frequency of
and cytokine production by those cells which produce IL-17F as
well as IL-17A, with seemingly separate pathways promoted in
each case. Antagonism of the AHR pathway led only to a sup-
pression in cathelicidin’s induction of cells producing IL-17A and
not in the induction of IL-17F sole producers (Fig. 3G,H). Pre-
viously, triggering of AHR with FICZ led to an increase in IL-17A
sole producers and IL-17A+F+ dual producers, but led to a
decrease in IL-17F single positive cells73. This, along with our
data, implies that there may be two pathways promoted by
cathelicidin: one of which is AHR-dependent, and which
enhances IL-17A+ F+ production; and one which is AHR-
independent and which enhances IL-17F production alone. This
may also explain the interesting lack of difference in IL-22 pro-
duction by cathelicidin-treated mouse cells, and its suppression in
human cells, as this has also been shown to be driven by AHR
ligation73. Single-cell transcriptome and signalling pathway ana-
lysis of whole splenic cultures treated with cathelicidin will be
required to test this hypothesis, and to extend our understanding
of how cathelicidin is enhancing TGF-β1 and AHR signalling.
The up-regulation of RORγt and down-regulation of Tbet
induced by cathelicidin was dependent on the presence of TGF-
β1 in the differentiation cocktail, and cathelicidin enhanced
phosphorylation of SMAD2/3, which mediate TGF-β1 signals63.
TGF-β1 has been used to differentiate mouse and human Th17
cells in many studies88,89 and cathelicidin could not induce Th17
cells in its absence, but rather enhanced its effects. Interestingly,
cathelicidin did not enhance IL-1 β-induced Th17 differentiation,
indicating that the cathelicidin-mediated increase in AHR and IL-
17A was a result of enhanced TGF- β1 signalling rather than a
more general Th17-boosting phenomenon.
The necessity for TGF-β1 in cathelicidin’s induction of Th17
cells extends previous observations of interplay between these two
mediators in other cell types90–92. Neutrophils can produce TGF-
β in lymph nodes and in tissues. Interestingly, lymph node-
neutrophil inhibition of B cell activation following inoculation is
also TGF-β dependent23. Deposition of granule proteins in the
lymph node by de-granulating neutrophils has been demon-
strated previously21 and the presence of extracellular cathelicidin
in our lymph nodes following HKST inoculum supports our
hypothesis that deposition of this peptide is also occurring during
inflammation, alongside production of TGF-β from multiple cell
types. This allows the enhanced differentiation of Th17 cells
during inflammation.
Exposure of CD4+ T cells to cathelicidin under Th17-driving
conditions led to an almost complete suppression of IL-2 pro-
duction, an enhancement of that noted previously as induced by
AHR signalling82. This observation is intriguing. It would predict
that T cells exposed to cathelicidin, in the presence of de-
granulating or NETosing neutrophils, will proliferate less, as the
available IL-2 is reduced. Further, neutrophil-induced suppres-
sion of T cell proliferation is well documented22,93. Indeed, we
demonstrate that cathelicidin inhibited proliferation of Th17 cells
in culture and therefore suggest that the neutrophils’ release of
cathelicidin, and subsequent suppression of IL-2 production, is
one mechanism behind this phenomenon.
The increased survival specifically of Th17 cells following
cathelicidin exposure is interesting. Neutrophil-boosted survival
of any T cell subset has never previously been described. Neu-
trophils can release BAFF and APRIL in the lymph nodes and
Fig. 9 Human CD4+ T cells enhance IL-17 production following cathelicidin exposure. CD4+ T cells were isolated from peripheral blood from healthy
human donors and cultured for 8 days in Th17-driving conditions, in the presence or absence of 2.5 μM human cathelicidin (LL-37). IL-17A production was
assessed by A, B flow cytometry on day 8 and C ELISA on days 3 and 8 of culture. D IL-17F was assessed by flow cytometry and E IL-22 by ELISA. Data
shown are individual donors with line at mean. B–E were analysed by a two-sided Wilcoxon test, on raw data before conversion to %. N values: B - 11, C - 11,
D - 6, E - 3. Black symbols represent untreated samples, open symbols represent samples exposed to cathelicidin.
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thus protect B cells against apoptosis94–96, and can also enhance
NK cell survival97, meaning our demonstration of T cell survival
fits within the context of the wider lymphocyte population.
Th17 cells are associated with a number of inflammatory and
autoimmune conditions, including psoriasis, rheumatoid arthritis,
and type 1 diabetes (reviewed in ref. 98). Our work supports
previous data showing that cathelicidin is recognised by
some CD4+ T cells as an autoantigen during psoriasis, and
those T cells which recognise cathelicidin produce more IL-1758.
The phenotype of the T cells resulting from cathelicidin
exposure–proliferating less, but surviving longer, and producing
more pro-inflammatory cytokines – suggests that they would be
deleterious long-term, and therefore that neutrophils present
during these conditions could be responsible for increased disease
onset and severity. In this regard, however, the specific increase in
IL-17F producing cells by cathelicidin is interesting, as this
cytokine has been correlated with non-pathogenicity of cells99,100,
and the spinal-cord infiltrating Th17 cells in EAE are mostly
solely producing IL-17A100. Future work understanding the role
of neutrophil-released cathelicidin in altering the pathogenicity of
Th17 cells, and in the specific induction of IL-17F, will be of great
interest.
Whether cathelicidin enters T cells through a specific receptor
is unclear. We demonstrate that the D-enantiomer of human
cathelicidin induces Th17 differentiation, strongly suggesting the
peptide can enter T cells in a receptor-independent fashion, as it
can do to other immune cells. However, our data showed a
suppression of Th17 differentiation in the presence of oATP, an
inhibitor of the receptor P2X7. This was not statistically sig-
nificant, and interpretation is complicated by a) significantly
enhanced cell death in T cells exposed to oATP, b) an increase in
baseline IL-17 production in T cells exposed to oATP but not to
cathelicidin, and c) the fact that oATP is not only a P2X7 inhi-
bitor but also attenutates inflammation by P2X7-independent
mechanisms101. We infer from these data that there may be an
indirect mechanism involving P2X7 in cathelicidin-mediated
Th17 differentiation, but unravelling this mechanism will require
knockout mice or more precise inhibitors than oATP.
Overall, our study identifies the antimicrobial peptide cathe-
licidin as a key Th17 differentiation factor and defines one
mechanism by which neutrophils can alter developing T cell
responses in a sophisticated and specific manner.
Methods
Experimental design. All experiments were performed three times on individual
mice or donor cell cultures and then power calculations performed to determine
necessary group sizes. Both male and female mice and human donors were used in
experiments and no differences were noted in responses between the sexes.
Numbers of individuals and of experiments are listed in each figure legend.
Mice were housed together for in vivo experiments to avoid cage-specific effects.
Mice. Wild-type C57Bl/6JOlaHsd and mCRAMP knockout (Camptm1Rig, KO)
mice were bred and housed in individually ventilated cages, under specific
pathogen-free conditions. Male and female mice between 6-12 weeks of age were
used. KO mice were backcrossed onto wildtypes for 10 generations before use. Mice
were kept in environmental conditions in line with the ASPA Code of Practice for
the UK – temperatures between 19 and 24oC, humidity between 45 and 65%, and
12 h of light then 12 h of dark.
All animal experiments were performed by fully trained personnel in
accordance with Home Office UK project licences PAF438439 and 70/8884, under
the Animal (Scientific Procedures) Act 1986. All relevant ethical regulations for
animal research were fully complied with. The experimental programme of work
was described in project licence PAF438439 and was approved as such. Each
experimental protocol was overseen by the in-house University of Edinburgh
veterinary team.
Healthy human donors. Peripheral venous blood was collected from healthy adult
volunteers under ethical agreement code AMREC 15-HV-013. All ethical regula-
tions from the University of Edinburgh were adhered to and informed written
consent was obtained from every donor. Experimental programmes were overseen
by the University of Edinburgh Centre for Inflammation Research Blood Resource
Management Committee. Up to 160 ml of blood was collected at one time into
sodium citrate and was then processed immediately. Ficoll Paque Plus (GE
Healthcare #GE17-1440-02) was used to isolate mononuclear cells by mixing with
freshly isolated blood (1:1 diluted in PBS) and spinning in LeucoSep tubes (Grenier
#227289) for 15 min at 1000 g, with brake at 0. CD4+ T cells were then isolated
from the cell layer using the EasySepTM human CD4+ T cell isolation kit (StemCell
Technologies #17952), according to manufacturers’ instructions.
Human Th-17 cultures. Human CD4+ T cells were plated at 1×105 cells/well in a
round-bottom 96-well plate in complete medium (RPMI, 10% foetal calf serum, 10
units/ml penicillin, 10 μg/ml streptomycin and 2 mM L-glutamine, all supplied by
Gibco, ThermoFisher UK). Cytokines added were: 10 ng/ml TGF-β1 (Biolegend
#580702), 100 ng/ml IL-6 (Biolegend #570802), 30 ng/ml IL-1β (Biolegend
#479402), 30 ng/ml IL-23 (Biolegend #574102) and 2.5 µl/ml anti-CD3/23/2
ImmunoCult T cell activator (StemCell Technologies #10970). Medium was
changed on day 3 and samples were assessed by flow cytometry and ELISA
on day 8.
Peptides. Synthetic mCRAMP (GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQ
PEQ) and LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) were
custom synthesised by Almac (Penicuik, Scotland) using Fmoc solid phase
synthesis and reverse phase HPLC purification. Peptide identity was confirmed by
electrospray mass spectrometry. Purity (>95% area) was determined by RP-HPLC
and net peptide content determined by amino acid analysis. D-enantiomer LL-37
was a kind gift from Professor Peter Barlow, Edinburgh Napier University. Lyo-
philised peptides were reconstituted in endotoxin free water at 5 mg/ml. Recon-
stituted peptides were tested for endotoxin contamination using a Limulus
Amebocyte Lysate Chromogenic Endotoxin Quantitation Kit (Thermo Scientific,
UK #88282).
Murine tissue and single-cell preparations. Mice were culled by rising con-
centrations of CO2, followed by cervical dislocation. Single-cell preparations of
spleens, lymph nodes and Peyer’s patches were achieved by mashing the tissues
through a 100 μM strainer and washing with PBS. One lung lobe was minced and
enzymatically digested with 1 mg/ml collagenase VIII (Sigma-Aldrich, #C2139) for
20 mins at 37 °C, with shaking before the cell suspension was passed through a 100
μM filter. To isolate liver leucocytes, one lobe was passed through a 100 μM
strainer and leucocytes isolated by Percoll separation102. To do this, cell pellets
from straining were re-suspended in 32% Percoll, 3% 10xPBS, and 65% Hanks
balanced salt solution. The cells were spun at 600 g for 10 min. From this, floating
hepatocytes were removed and leucocytes collected from the pellet.
In all cases red blood cells were lysed using RBC Lysis Buffer, as per the
manufacturer’s instructions (BD Biosciences, #555899).
Isolation of bone marrow-derived neutrophils. Femurs were removed and
marrow flushed out with complete medium (RPMI, 10% foetal calf serum, 10 units/
ml penicillin, 10 μg/ml streptomycin and 2 mM L-glutamine, all Gibco, Thermo-
Fisher, UK). Single-cell suspensions were prepared by passing the cells through
a 19 G needle. Neutrophils were isolated using the EasySepTM Mouse Neutrophil
Enrichment Kit (StemCell Technologies, #19762), as per the manufacturer’s
guidelines. Neutrophils were activated by 30 min incubation with 100 nM
fMLF (N-formylmethionine-leucyl-phenylalanine, Sigma-Aldrich #F3506) and
10 µM cytochalasin B (Sigma-Aldrich #C2743) before being thoroughly
washed twice.
In vitro T helper cell subset differentiation. Whole splenocytes were prepared as
above. CD4+ T cells were isolated from whole splenocytes by FACS sorting on a
BD Biosciences Aria sorter using a 70 µM nozzle or using the EasySep mouse
CD4+ T cell isolation kit (StemCell Technologies, Cat #19852). Purity achieved
with both methods was always over 95%.
200,000 cells were plated per well of round-bottom 96-well plates in complete
medium (RPMI, 10% foetal calf serum, 10 units/ml penicillin, 10 μg/ml
streptomycin and 2 mM L-glutamine, all supplied by Gibco, ThermoFisher UK),
with the correct combination of cytokines and neutralising antibodies as follows.
Th1 cells were differentiated for 4 days in the presence of plate-bound αCD3 (5 µg/
ml; Biolegend, #100339), rIL-12 (25 ng/ml; Biolegend, #575402), rIL-18 (25 ng/ml;
Gibco, #PMC0184) and rIL-2 (10 U/ml; Biolegend, #575402), with or without 2.5
μM mCRAMP. Th2 cells were cultured for 4 days with plate-bound αCD3 (5 µg/
ml; Biolegend, #100339), rIL-4 (4 ng/ml; Peprotech, #214-14), rIL-2 (40 U/ml;
Biolegend, #575402), αIL-12 (5 µg/ml; Biolegend, #505307) and αIFNγ (5 ug/ml;
Biolegend, #505812), with or without 2.5 μM mCRAMP. Th17 cells were
differentiated in the presence of plate-bound αCD3 (5 µg/ml; Biolegend, #100339),
rIL-6 (20 ng/ml; Biolegend, #575706), rIL-23 (20 ng/ml; Biolegend, #589006) and
rTGFβ (3 ng/ml; Biolegend, #580706), with or without 2.5 μM mCRAMP for 1 to
3 days. αCD28 (1 µg/ml; Biolegend, #102115) was added to cultures of pure CD4+
T cells. In some experiments neutrophils, isolated as above, were incubated in
CD4+ T cell cultures at a 1:1 neutrophil: T cell ratio. In other experiments
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recombinant IL-2 (Biolegend, #575402) or recombinant IL-1β (RnD Systems, #401-
ML) were included in cultures.
Flow cytometry. Cells were stained for surface markers for 30 mins at 4 °C, pro-
tected from light. Intracellular cytokines were assessed by incubating cells for 4 h at
37°C with Cell Stimulation Cocktail containing protein transport inhibitors
(eBioscience, #00-4970-03). Cells were fixed, permeabilised and stained for cyto-
kines using BD Cytofix/Cytoperm (BD Biosciences, #554722), as per the manu-
facturer’s guidelines. Cells were fixed, permeabilised and stained for transcription
factors using the True-Nuclear Transcription Factor Buffer Set, as per the manu-
facturer’s instructions (Biolegend, #424401). Cell viability was assessed by flow
cytometry using the Annexin-V-FLUOS Staining Kit, as per the manufacturer’s
guidelines (Roche, #11 858 777 001) or fixable live/dead yellow (ThermoFisher
#L34959). To assess proliferation, cells were stained with carboxyfluorescein suc-
cinimidyl ester at 1:2000 dilution for 10 min (Invitrogen, #C34554) before culture.
Proliferation analysis by dye dilution was performed by flow cytometry. Samples
were collected using an LSRFortessa cytometer(BD Biosciences) and Diva software
version 9, and analysed using FlowJo software version 10 (BD Biosciences).
Flow cytometric analysis of phosphorylated antigens was performed by first
staining surface markers for 30mins at 4 °C, before adding 1ml of phosflow lyse/fix
buffer (BD Biosciences, Cat #558049) for 60min at room temperature. Cells were then
centrifuged and resuspended in 1ml ice-cold methanol for 30min on ice before being
washed with PBS. Antibodies in PBS were used to stain intracellular phosphorylated
antigens for 45min before being washed and data collected immediately.
Antibodies (mouse). CD4 (clone GK1.5, Biolegend, #100453, dilution 1:200); CD8
(53-6.7, BD Biosciences, #563786, 1:200); IFNγ (XMG1.2, Biolegend, 505825,
1:100); IL-17A (TC11-18H10.1, Biolegend, #506938, 1:100); IL-22 (POLY5164,
Biolegend, #516411, 1:100); RORγT (B2D, eBiosciences, #12-6981-80, 1:100);
TBET (4B10, Biolegend, #644805, 1:100); AHR (4MEJJ, eBiosciences, #25-5925-80,
1:100); pSTAT3 (LUVNKLA, eBioscience, #11-903-42, 1:100); pSMAD2/3 (o72-
670, BD Biosciences, #562586, 1:100)
Antibodies (human). CD4 (clone OKT4, eBioscience #25-0048-42, 1:200), IL-17A
(eBio64DEC17, eBioscience #12-7179-42, 1:100), IL-17F (Poly5166, Biolegend
#516604, 1:150).
Nanostring. Mouse Th17 cultures were set up as previously described. DAPI−γδ-
CD4+ T cells were sorted using a BD FACSAriaTM II (BD Biosciences) on day 1.
RNA was extracted immediately using the Qiagen RNeasy Mini Kit (Qiagen,
#74104), as per the manufacturer’s guidelines. Multiplex gene expression analysis
(Mouse Immunology Panel) was performed by HTPU Microarray Services, Uni-
versity of Edinburgh. Data analysis was performed using nSolver 4.0 and nCounter
Advanced Analysis software. Genes with a log2 fold change of 1 or more and a p
value of 0.05 or less, following correction for multiple comparisons, were deemed
of interest and statistically significant.
ELISA. Concentrations of mouse IL-17A (Biolegend, #432504), IFNγ (Biolegend,
#430804), IL-2 (Biolegend, #431004), IL-17F (Biolegend, #436107) and IL-22
(Biolegend, #436304), and of human IL-17A (Invitrogen #BMS2017) and IL-22
(ThermoFisher, #BMS2047) were determined in cell culture supernatants by
ELISA, as per the manufacturer’s guidelines.
Immunohistochemistry. Lymph nodes were fixed in 10% neutral buffered for-
malin and embedded in paraffin. 10 µm sections were deparaffinized and antigens
retrieved by microwaving in tri-sodium citrate buffer, pH 6 for 10 min, or by 10
min incubation with 5 mg/ml proteinase K (ThermoFisher UK #AM2548). Slides
were blocked (Avidin/Biotin Blocking Kit, Vector Laboratories, #SP-2001) and
incubated overnight with rabbit anti-mCRAMP (1/250; Innovagen, #PA-CRPL-
100). Slides were then incubated with an anti-rabbit HRP-conjugated secondary
antibody (1/500; Dako, #P0217) or AF488-conjugated antibody (1:500, Thermo-
Fisher UK #A11034). Some sections were developed with diaminobenzidine
(ImmPACT DAB Peroxidase (HRP) Substrate, Vector Laboratories, #SK-4105) and
others were also incubated with an AF647 anti-neutrophil antibody (1:50, Biole-
gend UK #127609). Slides were scanned on a ZEISS Axio Scan.Z1 slide scanner.
Heat-killed Salmonella model. Heat-killed salmonella was a kind gift from Pro-
fessor Andrew Macdonald, MCCIR, University of Manchester. 12.5 μg heat-killed
Salmonella typhimurium in 50 µl PBS was injected subcutaneously in the top of
each hind paw. Mice were monitored and the draining popliteal lymph nodes
removed after 1, 3 or 7 days. Nodes were either fixed in 10% neutral buffered
formalin and embedded in paraffin for sectioning, or single-cell suspensions were
prepared as described previously for flow cytometric analysis.
Influenza infection model. Murine influenza strain PR8, a kind gift from Dr
Ananda Mirchandani, University of Edinburgh, was instilled intra-nasally into
mice—12p.f.u. in 40 μl inoculations. Mice were monitored daily and the draining
mediastinal lymph nodes removed 72 h later. Flow cytometry on node single-cell
suspension was performed as previously described.
Statistics. All data shown are expressed as individual data points with line at
median. Analysis was performed with GraphPad Prism software. Multiple groups
were compared by one- or two-way analysis of variance tests with either Bonferroni
or Dunnett post-tests. Two groups were compared with two-way paired Student’s
t-tests. A minimum of three mice was used for in vitro experiments, in individually
performed experiments. Details of sample sizes are included in all figure legends.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availibility
The datasets generated during the current study are available from the corresponding
author (EGF) upon request. The authors declare that all data supporting the findings of
this study are available within the paper.
The Nanostring data set has been deposited and can be found at the Gene Expression
Omnibus repository with accession code GSE160757.
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